IGLV7-35: A Potential Drug Target and Biomarker (G28777)

Target Name: IGLV7-35

NCBI ID: G28777

IGLV7-35

Other Name(s): IGLV735 | V3-1P | Immunoglobulin lambda variable 7-35 (pseudogene) | immunoglobulin lambda variable 7-35 (pseudogene)

IGLV7-35: A Potential Drug Target and Biomarker

IGLV7-35 is a novel gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. IGLV7-35 is a member of the IGLV7 gene family, which is known to encode for the interleukin-7 receptor (IL-7R), a cytokine that plays a crucial role in the regulation of immune and inflammatory responses. The IGLV7-35 gene has been shown to be expressed in a variety of tissues and cells, including immune cells, neurons, and tissues, making it a promising target for drugs that can modulate immune and inflammatory responses.

The Discovery of IGLV7-35 as a Potential Drug Target

The identification of IGLV7-35 as a potential drug target was based on several studies that demonstrated its ability to interact with various signaling pathways and proteins involved in immune and inflammatory responses. One of the most significant findings was that IGLV7-35 was shown to interact with the protein PD-L1, which is a negative regulator of the T-cell immune response. PD-L1 has been shown to play a crucial role in promoting immune tolerance and limiting the autoimmune response, and IGLV7-35 has been shown to modulate its activity to promote the development of autoimmune diseases.

Additionally, IGLV7-35 has been shown to interact with several other proteins involved in the regulation of immune responses, including the transcription factor NF-kappa-B and the protein PDGF-BB. These interactions suggest that IGLV7-35 may be involved in the regulation of immune responses and that it may be a useful target for drugs that can modulate these responses.

The Potential Role of IGLV7-35 as a Biomarker

IGLV7-35 has also been shown to be a potential biomarker for several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. One of the most significant findings was that IGLV7-35 was shown to be expressed in the brains of individuals with Alzheimer's disease, a neurodegenerative disorder. This suggests that IGLV7-35 may be involved in the development and progression of this disease.

Additionally, IGLV7-35 has been shown to be involved in the regulation of pain perception and neuroinflammation, which are several common symptoms associated with chronic pain and neurodegenerative disorders. This suggests that IGLV7-35 may be a useful biomarker for the development and treatment of these conditions.

The Future of IGLV7-35 as a Drug Target

The identification of IGLV7-35 as a potential drug target and biomarker has significant implications for the development of new treatments for a variety of diseases. By modulating the immune and inflammatory responses, IGLV7-35 may be a useful target for drugs that can treat a range of conditions, including cancer, neurodegenerative disorders, and autoimmune diseases.

While further research is needed to fully understand the role of IGLV7-35 as a drug target and biomarker, its potential as a new treatment option is exciting and promising. As research continues, IGLV7-35 may become a valuable tool for the development of new treatments for a variety of diseases.

Protein Name: Immunoglobulin Lambda Variable 7-35 (pseudogene)

The "IGLV7-35 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about IGLV7-35 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets